Condition: Hyperuricemia · Hypouricemia, Renal · Sponsor: Intelligem Therapeutics Australia Pty Ltd.
This is a phase I/II clinical study to evaluate the safety, tolerability, PK, and efficacy of IG3018 tablet in hyperuricemia (HUA) subjects with or without CKD.
This description comes directly from the study's public registry record.
Operation Team · +8610 53688632 · clinicaltrials@intelligemtx.com
Always discuss trial participation with your own doctor first.
| Emeritus Research Pty Ltd -Sydney | Botany, New South Wales, Australia | Recruiting |
| Pendlebury Research Pty Ltd T/A Novatrials | Kotara, New South Wales, Australia | Recruiting |
| Emeritus Research Pty Ltd -Melbourne | Camberwell, Victoria, Australia | Recruiting |
| Chung Shan Medical University Hospital | Taichung, Taiwan, Taiwan | Recruiting |
| Taipei Medical University Hospital | Taipei, Taiwan, Taiwan | Recruiting |
| Chang Gung Memorial Hospital | Taoyuan, Taiwan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06310967